Form 4: Fulcrum Therapeutics Director Rachel K. King Granted 36,000 Stock Options

Rachel K. King, a Director at Fulcrum Therapeutics, Inc., was granted 36,000 stock options with an exercise price of $7.38, vesting over one year.

Summary

• Rachel K. King, a Director of Fulcrum Therapeutics, Inc. (FULC), was granted 36,000 stock options.
• The options have an exercise price of $7.38 per share.
• The grant date for these options is June 26, 2025.
• The options are scheduled to vest with respect to all shares on the first anniversary of the grant date (June 26, 2026) or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• The expiration date for these stock options is June 25, 2035.
• The filing was made on June 30, 2025.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine and generally positive event, as it aligns the director's interests with shareholder value creation. It does not indicate any immediate negative or highly unusual circumstances.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector.

Future Outlook

The stock options are scheduled to vest fully on the first anniversary of the grant date (June 26, 2026) or earlier, contingent on the director's continued service, providing a future incentive for performance.

Management Comments

• The grant of stock options to Rachel K. King reflects a standard practice of equity-based compensation for board members, aligning their long-term interests with the company's performance.

Industry Context

Equity compensation, particularly through stock options, is a prevalent method in the biotechnology and pharmaceutical industries to incentivize and retain key personnel, including directors, by linking their financial success to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The practice of granting stock options to directors is a common form of compensation across the biotechnology and pharmaceutical sectors, similar to companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently use equity to align executive and board interests with shareholder value.
• The specific size of the grant (36,000 options) and the exercise price ($7.38) are typical for director compensation, though the exact figures vary widely based on company size, stage of development, and individual director responsibilities.
• The one-year cliff vesting schedule is a standard approach for director equity grants, ensuring commitment for at least a year post-grant, comparable to vesting schedules seen in similar-sized biotech firms.

Related Party Transactions

• The grant of stock options to a director is a standard equity compensation arrangement, which is a common transaction between a company and its insiders.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting employees, such grants are part of a broader compensation philosophy that can influence overall company culture and talent retention strategies.

Next Steps

• The stock options will vest on June 26, 2026, or earlier, subject to continued service.
• Rachel K. King will be able to exercise the options to purchase common stock at $7.38 per share once vested, up until the expiration date of June 25, 2035.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, Stock Option, Director, SEC Form 4, Insider Transaction, Equity Grant, Compensation